Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies.

Abstract

The authors developed a strategy that includes a novel approach of induction full-dose chemotherapy followed by traditional chemoradiation as a neoadjuvant therapy for pancreatic cancer. Here they report the results of a phase I/II trial of gemcitabine, cisplatin, and 5-FU for patients with advanced gastrointestinal malignancies.

• Authors: Charles A Staley, Wayne B Harris, Jerome Landry, William Small, David Kooby, Theresa W Gillespie, Mary Meyers, Kapil N Bhalla
• Journal: Surgical oncology clinics of North America (Surg Oncol Clin N Am) Vol. 13 Issue 4 Pg. 697-709, x (Oct 2004) ISSN: 1055-3207 [Print] United States
• PMID: 15350943 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Deoxycytidine
• Cisplatin
• Fluorouracil
• Gemcitabine

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemotherapy, Adjuvant
• Cisplatin (therapeutic use)
• Combined Modality Therapy
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Female
• Fluorouracil (therapeutic use)
• Gastrointestinal Neoplasms (mortality, pathology, therapy)
• Humans
• Male
• Maximum Tolerated Dose
• Middle Aged
• Neoadjuvant Therapy
• Neoplasm Staging
• Pancreatectomy (methods)
• Pancreatic Neoplasms (mortality, pathology, therapy)
• Patient Selection
• Prognosis
• Radiotherapy Dosage
• Radiotherapy, Adjuvant
• Remission Induction
• Survival Analysis
• Treatment Outcome
• Gemcitabine